prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35|36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55 |56 |57 |58 |59 |60 |61 |62 |review

The primary endpoint of this study was any diabetes related events. For this composite endpoint there was a significant 11% reduction in favor of those treated with a more intensive regimen of initial sulphonylurea or insulin as opposed to initial diet therapy. However, the effect on myocardial infarction was only borderline and no clear effect was seen for stroke. However for microvascular complications alone a more significant 25% reduction was noted.